Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Appoints New Director and Announces Retirement of Board Member
Summary
On October 23, 2025, Jazz Pharmaceuticals plc appointed Dr. Ted Love to its Board of Directors, effective December 1, 2025, and announced the retirement of Kenneth W. O'Keefe from the Board, effective the same date. Dr. Love will serve on the Audit and Science and Medicine Committees. Compensation and indemnification arrangements are in line with the company's standard practices for non-employee directors.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement